The new laboratory CPT codes for each of the three major areas of clinical genetic laboratory testing is available in the following report. The availability of these new codes will greatly facilitate billing for existing and new tests and technologies used in laboratories. They also provide the basis for addressing reimbursement issues. Without codes that accurately describe the services currently provided, discussions of appropriate reimbursement are difficult. Cost analysis information about tests from your laboratory is welcomed. This will allow the College to provide HCFA and other payers with information to allow them to make an educated decision regarding appropriate rates -of reimbursement. Please provide this information to the fax number given below.
NEW LABORATORY CPT CODES
Major revisions to the CPT coding of genetic testing have been approved by the AMA CPT Editorial Panel and go into effect on January 1, 1999. The following will provide you with the revised CPT codes (new, modified, and deleted) and offer an overview of how they might be combined or "stacked" to describe particular tests. There is also a brief discussion of important considerations in incorporating these into your laboratory's or institution's billing and reimbursement systems.
As a point of reference to facilitate reviewing the individual lists of codes, note the following. The codes are presented in two columns. The first column shows the codes' 1998 status and language, while the second column shows this for 1999. Where a code did not exist in 1998, we have noted that in the 1998 column and inserted the language of the new code in the 1999 column. Deleted codes or modified codes have a line through the language being removed. When modified, the new language is underlined in the 1999 column. When a code description is indented, the first part of the code description is determined by the language of the code immediately preceding it. If that code is also indented, continue back through the codes to the first one which is not indented. The language preceding the semicolon applies to each of the indented codes following it. Where the code has not changed, "same" is noted in the 1999 column. The codes for each of the areas of genetic testing are appended.
Clinical Cytogenetics
Overview: There are several significant changes within the Cytogenetics codes. In general terms, the codes have been refocused to distinguish between testing for cancer versus constitutional abnormalities. The major changes include 1) the addition of CPT codes to describe FISH tests; 2) a new code for cancer cytogenetic analyses; 3) a new pair of codes to describe the freezing of viable cell lines and their subsequent thawing and reestablishment in cell culture to be used for tests (usually biochemical) requiring viable cells which are commonly sent to reference laboratories. These codes will likely be used by cytogenetics laboratories or biochemical genetics laboratories. 4) There is also a new CPT code for the reporting and interpretation of results of cytogenetic and molecular cytogenetic testing which is generally used when results and interpretation are abnormal and/or complex. Overview: The primary changes to this area involve generalizing language to cover nucleic acids rather than DNA and the addition of several codes reflecting more recent technologies used in molecular diagnosis. Note that, for the most part, the codes discussed here have been developed to apply to the analysis of the human genome since a significant number of new codes exist for the molecular identification of infectious agents (see 87470-87799). However, the availability of codes for specific infectious agents does not necessarily preclude the use of codes within this area. Overview: The goal for reworking the CPT coding for Biohemisid Genetics was to move away from listing individual amino lcids or c)rg'lnic <lcids, some of which have CPT codes already, to I more general '~p~r o~c h .
Furthermore, \ve wanted to provide for li~~llitative 'lnd clu,untitutive assays, for single analytes, multiple ~n,ll!.tes. ,lnd profiles, and to have the newer technologies more :ommon to our field included. A few new analytes common to ?ic)chen1iccll genetic testing have also been added. Note that new ind modified codes are ,~vail,lble in the cytogenetics section for :ell culture. The Iangu,lge has been changed such that cell culture ~sn't specifically for the purpose of cytogenetic testing but, rather, is for testing for either nonneoplastic or neoplastic disorders. Furthermore, codes for cryopreservation as well as the thawing and reestablishment of cell lines, often needed for sequential distribution of cells to r e t k n c e laboratories, are available.
Lastly. a code for interpretation and reporting was proposed hut denied. The reasoning was that this activity is commonly a professional service component that is performed in the course of a consultation and, therefore, billable under that group of services.
The CPT Editorial Panel recently decided to incorporate all of our new codes into the chemistry section rather than have a subsection on Biochemical Genetics in order to accommodate others using these codes.
The CPT Codes: See Appendix 3 for the list of CPT codes in the Biochemical Genetics area. Note that this list is not all-inclusive due to the number of analytes in the existing CPT code book. Rather, the lists reflect codes that are new or modified only and applicable to this area of testing. For those codes for which the description of the code states "analyte not specified elsewhere," the existing analyte code description likely includes the analytical technique historically used for that test. You would stack the new codes in instances in which you apply a new analytical code. Lastly, the term "specimen" has been used to allow for the testing of multiple tissues in situations in which the ratio between tissues is important or multiple tissue assessments are clinically relevant.
Example: Your laboratory is asked to analyze a urine specimen for acylcarnitines. The test done in your laboratory involves profiling the carnitine esters using fast atom bombardment and electrospray ionization coupled with tandem mass spectrometry. The CPT codes that describe this test are: 82016 acylcarnitines; qualitative, each specimen 83788 mass spectrometry and tandem mass spectrometry
General
Important considerations: The availability of particular CPT codes does not necessarily guarantee their reimbursement. In most situations, diagnostic coding (ICD) must support the use of the test in any particular situation. Also, note that no relative value units ( RVUs) have been assigned to the base code for reporting and interpretation of complex cytogenetic results. RVUs are assigned to professional services while the reimbursement for analytical codes is assigned by the Health Care Financing Administration (HCFA). In general terms, professional services are considered those reimbursable to an individual with a UPN, a number which identifies a physician within the Medicare system. Hence, only physicians can be reimbursed for the use of this code when Medicare is billed. This does not necessarily preclude their use being built into contracts with referral bases. We are beginning to pursue acquiring restricted licenses for Board-certified PhD lab directors, which would allow them to bill for professional services within their area of certification. This would parallel the actions in a few states in which this privilege already exists.
DISCLAIMERS IN REPORTS OF GENnIC TESTS USING ANALYTE SPECIFIC REAGENTS
Pursuant to a new FDA rule, effective November 23, 1998, laboratories reporting out results of tests using analyte specific reagents ( ASRs), including molecular probes, that have not been approved by the FDA must include a specific disclaimer o n the test report. ASRs are reagents composed of chemicals o r antibodies that constitute the "active" ingredients of an in-house developed test. Manufacturers are required to label all such products as ASRs. The required disclaimer states as follows:
"This test was developed and its performance determined by (laboratory name). It has not been cleared or approved by the U.S. Food and Drug Administration."
Because this statement may cause confusion among physicians, patients, and payers regarding whether such tests are clinically necessary and reimbursable, laboratories may wish to add clarifying language after the disclaimer, such as the following:
"The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes."
Laboratories also may wish to add the following: "Pursuant to the requirements of CLIA '88, this laboratory has established and verified the test's accuracy and precision."
Any clarifying language must be in addition to the exact language required in the FDA disclaimer.
Clinical laboratories using ASRs must verify o r establish, for each use of an ASR, the performance characteristics, e.g., accuracy, precision, analytical sensitivity and specificity, etc. 42 CFR $493.1213.
Geneticists who provide interpretations of tests performed using ASRs, and laboratories that report out results of tests performed by other laboratories, also must include the FDA-required disclaimer on test reports. Although the disclaimer requirement does not ~p p l y to ASRs developed and used exclusively in-house (i.e., home-brew ASRs), which are not currently regulated by the FDA, some variation of the required disclaimer and clarifying language is recommended. The disclaimer also does not apply to ASRs that are sold and used as components of tests or kits (in vitro diagnostics) that have been cleared or approved by the FDA. Finally, the disclaimer is not required for tests using reagents that are labeled for "Research Use Onlyw ( RUOs) or for "Investigational Use Only" (IUOs). Such reagents are subject to FDA approval but have not been approved for clinical use.
